Key facts
- This page summarizes Michael John Sumner's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 28 Feb 2024, 17:03.
Michael John Sumner - 28 Feb 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- INO
- Reported as of
- 28 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2024, 17:03:33 UTC
- Prior SEC filing
- 03 Jul 2023
- Next SEC filing
- 16 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael John Sumner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael John Sumner filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 28 Feb 2024.
Change
- Previous filing in this sequence was filed on 03 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INO
transaction
Derivative
Common Stock Option
Award
- Transaction value
- $0
- Shares
- +18,750
- Change %
- Price
- $0.000000
- Shares after
- 18,750
- Date
- 28 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,750
- Exercise price
- $8.46
- Footnotes
- F1
INO
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +15,029
- Change %
- Price
- $0.000000
- Shares after
- 15,029
- Date
- 28 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,029
- Exercise price
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The vesting schedule for the 18,750 options is as follows: 4,688 shares vested on February 28, 2024; 4,688 shares will vest on February 28, 2025; 4,687 shares will vest on February 28, 2026; and 4,687 shares will vest on February 28, 2027.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.